No Data
OncoTherapy Science 1H Loss Y545.00M Vs Loss Y710.00M
OncoTherapy Science: Confirmation letter
OncoTherapy Science: Semi-annual report - 24th term (2024/04/01 - 2025/03/31)
SoftBank, 25/3 upward revision operating profit 950 billion yen ← 900 billion yen.
SoftBank <9434> announced a revision to its forecast for the fiscal year ending March 2025. The revenue was revised upward from 6 trillion 200 billion yen to 6 trillion 350 billion yen, and the operating profit from 900 billion yen to 950 billion yen. The strong performance of its subsidiary PayPay, a major player in smart phone payments, as well as the recovery of the mobile business, contributed to this. Positive evaluations for Secom midterm <9735>, Kaken Pharmaceuticals midterm <4521>, Olympus midterm <7733>, Fukui silver revision <8362>, Tokyu midterm <9005>.
OncoTherapy Science: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending 2025/3 [Japanese GAAP] (consolidated)
OTS and others continue to rank in, signing a joint research agreement with the Medical Foundation for Health and Nutrition Research Institute.
OTS <4564> ranked in (as of 1:33 pm). Significantly higher. It seems that they have announced a joint research agreement with the National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN, Veon Ltd Ads) regarding the development and application of drug discovery platforms utilizing AI before the start of today's trading, which is driving buying interest. By utilizing NIBIOHN's AI-based drug discovery platform technology, they aim to analyze our proprietary compound information and explore compounds that lead to new drug discovery.
No Data
No Data